A study of the long-term safety and mechanism of action of alemtuzumab, an experimental drug used in Multiple Sclerosis
Dr. Anu Kemppinen
Institution or company
University of Cambridge
This research study is looking at genes that control the immune system, which have been identified as being important in the disease called multiple sclerosis. The main purpose of this study is to see how these genes influence the effectiveness of an experimental drug (alemtuzumab) in the treatment of Multiple Sclerosis.
Participation: For this study we recruited 14 healthy volunteers from the Cambridge BioResource to attend a single appointment where they gave 50 ml of blood.
Organisation: This study is organised by Dr Anu Kemppinen from the Univeristy of Cambridge.